Orgenesis’s scientific work and R&D efforts are headed by Prof. Sarah Ferber, Ph.D biochemistry and distinguished researcher. Prof. Ferber is the head of the endocrine research unit at Sheba Medical Center. Prof. Ferber’s research work has been funded over the past 10 years by the JDRF, the Israel Academy of Science foundation (ISF) and D-Cure (over US$4M).
The company's technology was developed following extensive animal safety testing and research has matured to the stage of clinical development. There are over 50 centers in the world that are highly qualified for Pancreatic Islet transplantation. It is the company's intention to work closely with such leading centers in order to enable Autologous Insulin Producing (AIP) cell transplantation as a therapeutic approach in the treatment of diabetes at those centers.
The global diabetes market was estimated at $27.00 billion in 2008 with a growth rate of 6.5 per cent. The market is expected to reach $44.70 billion in 2015 with a compound annual growth rate (CAGR) of 7.5 per cent.
The total sales for insulin products were $6.83 billion as of 2004. The annual direct cost of Diabetes Mellitus in the US alone is $43 billion. In the top-seven markets, the potential for monitoring and treating the disease as well as treating the direct complications of the disease will exceed $70 billion in 10 years. This is a significant incentive to development.
Global diabetes market revenues